[Federal Register Volume 74, Number 33 (Friday, February 20, 2009)]
[Notices]
[Page 7925]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-3649]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated October 9, 2008 and published in the Federal 
Register on October 17, 2008, (73 FR 61911), Noramco Inc., 1440 Olympic 
Drive, Athens, Georgia 30601, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053)......................  I
Morphine-N-oxide (9307).....................  I
Amphetamine (1100)..........................  II
Methylphenidate (1724)......................  II
Codeine (9050)..............................  II
Dihydrocodeine (9120).......................  II
Oxycodone (9143)............................  II
Hydromorphone (9150)........................  II
Hydrocodone (9193)..........................  II
Morphine (9300).............................  II
Oripavine (9330)............................  II
Thebaine (9333).............................  II
Oxymorphone (9652)..........................  II
Alfentanil (9737)...........................  II
Sufentanil (9740)...........................  II
Carfentanil (9743)..........................  II
Fentanyl (9801).............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the schedule I 
controlled substances for internal testing; the schedule II controlled 
substances will be manufactured in bulk for distribution to its 
customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Noramco Inc. to manufacture the listed basic classes of controlled 
substances is consistent with the public interest at this time. DEA has 
investigated Noramco Inc. to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic classes of controlled substances listed.

    Dated: February 13, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E9-3649 Filed 2-19-09; 8:45 am]
BILLING CODE 4410-09-P